Candel Therapeutics, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. Filed March 29, 2022. This is an annual report, not a standalone Q4 report.
Business context
Candel is a clinical-stage biopharmaceutical company developing intratumoral oncolytic viral immunotherapies. Its lead candidates are adenovirus-based CAN-2409 and HSV-based CAN-3110. It had no approved products and no product-sales revenue. Reported service revenue relates to a legacy license and services arrangement with Ventagen, a related party.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Research and development service revenue | $0.125 million | $0.125 million |
| Research and development expense | $15.178 million | $8.754 million |
| General and administrative expense | $10.673 million | $5.181 million |
| Operating loss | $25.726 million | $13.810 million |
| Net loss | $36.124 million | $17.680 million |
| Basic and diluted loss per share | $1.91 | $1.52 |
| Net cash used in operating activities | $22.218 million | $9.071 million |
At December 31, 2021, cash and cash equivalents were $82.642 million, current assets $84.945 million, total assets $89.205 million, total liabilities $25.068 million, and stockholders’ equity $64.137 million. The company reported $0.560 million of long-term debt and an $18.252 million warrant liability. No product margins were reported; operating performance reflects research and development and corporate costs.
The 2021 net loss included an $11.421 million noncash expense from the increase in fair value of warrant liabilities, versus $4.605 million in 2020. The company also recorded $1.076 million of grant income, including $0.463 million from forgiveness of its PPP loan. Operating cash use increased as clinical, staffing, and public-company costs rose. The IPO generated $71.335 million in net proceeds; financing cash inflows were $71.800 million.
Material changes and developments
- Research and development expense increased $6.424 million, mainly from higher employee-related and clinical-development costs and a $0.553 million fixed-asset impairment.
- General and administrative expense increased $5.492 million, including higher staffing, professional fees, and directors’ and officers’ insurance following the IPO.
- The company completed enrollment of more than 700 patients in its CAN-2409 Phase 3 localized prostate cancer trial in September 2021. Final results were expected in 2024.
- All preferred stock converted to common stock at the July 2021 IPO. The company issued 9,887,994 IPO shares at $8.00 per share, including the partial over-allotment.
Outlook, risks, and unusual items
- Management estimated that year-end cash plus a subsequent borrowing would fund operations into the fourth quarter of 2023, while cautioning that assumptions could prove wrong. The company expects significant ongoing losses and will need substantial additional funding.
- After year-end, on February 24, 2022, Candel borrowed $20 million under a Silicon Valley Bank facility of up to $25 million. A further $5 million is conditional on specified clinical and equity-financing milestones. The loan is secured by substantially all assets except intellectual property, bears a floating rate of at least 5.75% (or prime plus 2.50%), and includes a 4.50% final payment fee.
- Other expected milestones included CAN-2409 NSCLC Phase 2 safety and initial activity data in Q2 2022; a planned CAN-2409 high-grade glioma Phase 3 start around mid-2022; and active-surveillance prostate Phase 2 top-line data in 2023. The filing gives differing timing references for NSCLC data; investors should verify current timelines.
- Management described COVID-19-related enrollment delays and site closures, but said they had not materially affected development timelines as of the filing. The pandemic could still disrupt trials, manufacturing, supply, or financing.
- Key risks include clinical-trial failure, regulatory uncertainty, reliance on CAN-2409 and CAN-3110, manufacturing scale-up and third-party suppliers, competition, future financing needs, and reimbursement and market-acceptance uncertainty. FDA agreement under the prostate-trial Special Protocol Assessment does not assure approval.
- The company disclosed unremediated material weaknesses in internal financial controls related to accounting expertise, formal transaction controls, monitoring, and segregation of duties. Management said remediation was underway. Disclosure controls and procedures were judged effective at a reasonable-assurance level.
- Earlier CAN-2409 glioma survival comparisons used a matched external control group, not a concurrent randomized control; the filing reports statistical significance but notes the broader uncertainty of clinical results. Some reported prostate comparisons were also against other trials, not head-to-head studies.
Important facts for investors to verify
- Current cash, cash runway, financing plans, and compliance with the SVB loan covenants and conditions for the additional tranche.
- Updated enrollment, data-readout, and trial-start timelines—especially the differing NSCLC data timing and planned glioma Phase 3 start.
- Final controlled-trial evidence for CAN-2409, including endpoints, safety, and whether earlier external-control comparisons are confirmed.
- Manufacturing readiness and third-party supply arrangements, along with the costs and timing to support clinical and potential commercial scale.
- Progress in remediating internal-control weaknesses and the effect of warrant remeasurement and potential warrant exercise or dilution.